Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects

NCT07054255 | Completed Phase 1

• 1 other identifier: HSK-63-BE-2020
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

The present study was conducted with the objective of comparing the bioequivalence and safety of a single dose of ranolazine extended-release tablets (Test product) manufactured by Haisco Pharmaceutical Group Co., Ltd. with those of the reference product (Ranexa®, Gilead Sciences, Inc.) in Chinese healthy subjects under fasting and fed conditions

Conditions

Healthy

Outcome Measures

Primary Outcomes (3)

• Cmax

  The pharmacokinetic parameters of Ranolazine in plasma

  From the start of administration to 48 hours post-dose

• AUC(0-t)

  The pharmacokinetic parameters of Ranolazine in plasma

  From the start of administration to 48 hours post-dose

• AUC(0-∞)

  The pharmacokinetic parameters of Ranolazine in plasma

  From the start of administration to 48 hours post-dose

Secondary Outcomes (1)

• AEs

  From the time of signing ICF to the end of follow-up，up to 10 days

Study Arms (2)

Test formulation

EXPERIMENTAL

Ranolazine sustained-release tablets, specification: 500 mg, Haisco Pharmaceutical Co., Ltd.

Drug: Test formulation (Ranolazine extended-release tablets)

Reference formulation

EXPERIMENTAL

Ranolazine sustained-release tablets (Ranexa®), specification: 500 mg, Gilead Sciences, Inc.

Drug: Reference formulation (Ranolazine extended-release tablets)

Interventions

Test formulation (Ranolazine extended-release tablets) DRUG

A single oral dose of 500 mg, taken with 240mL of water

Test formulation

Reference formulation (Ranolazine extended-release tablets) DRUG

A single oral dose of 500 mg, taken with 240mL of water

Reference formulation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy subjects aged 18 or older, both male and female, with an appropriate gender ratio;
• Female subjects weight ≥ 45.0 kg and male subjects weight ≥ 50.0 kg, and BMI of 19 to 26 kg/m\^2(inclusive);
• Subjects who have no plans to conceive or donate sperm/eggs during the trial period until 3 months after the end of the trial and voluntarily adopt effective physical contraception measures.
• Prior to the trial, a detailed understanding of the nature, significance, potential benefits, potential inconvenience, risks, and discomfort of the trial was obtained, and the subjects voluntarily participated in the clinical trial. The subject was able to communicate well with the researchers, comply with the requirements of the entire study, and signed a written informed consent form.

You may not qualify if:

• Subjects who are known to be allergic to the investigational drug component Ranolazine (including excipients) or similar substances, or those with an allergic constitution (such as allergies to two or more drugs, food, or pollen) (consultation);
• Subjects with a history of chronic or severe diseases or existing systemic diseases that may affect the research results, including those related to the blood system, circulatory system, digestive system, urinary system, respiratory system, nervous system, immune system, endocrine system, mental disorders, metabolic disorders, or any other conditions that may affect the research results (consultation);
• Subjects who have undergone major surgery or suffered severe trauma within the first 3 months (90 days) of screening, or who have undergone surgery that may significantly affect the in vivo process or safety evaluation of the study drug (consultation);
• Received vaccination within one month (30 days) before screening(consultation);
• Used any prescription medication (such as antihypertensive drugs) within 1 month (30 days) before screening, or used any over-the-counter medication (vitamins, herbal medicines) within 2 weeks before screening (consultation);
• Subjects who have participated in and used any clinical trial drug or medical device within 3 months (90 days) before the first administration, or those who plan to participate in other clinical trials during this study (consultation);
• Subjects who regularly drink alcohol within one month (30 days) before screening (drinking alcohol ≥ 3 times a week, and drinking 50 ° Baijiu ≥ 100 mL each time on average), or cannot abstain from alcohol during the test, or the alcohol breath test result is\>0.000mg/mL (consultation, examination);
• Subjects who have been addicted to smoking (more than 5 cigarettes per day or an equivalent amount of tobacco) for the past 3 months (90 days) prior to screening or who cannot stop using any tobacco products during the trial period (consultation);
• Subjects who have lost blood/donated more than 400 mL (excluding physiological blood loss in females) within 2 months (60 days) prior to screening, or who have received blood transfusions/used blood products, or who plan to donate blood within 1 month (30 days) after the end of the trial (consultation);
• On a daily within 2 weeks prior to screening,consuming excessive amounts of foods that affect metabolism, such as grapefruit or beverages containing grapefruit; Consuming excessive amounts of tea, coffee, chocolate, cola, or foods/beverages containing their main ingredients every day (averaging 8 or more cups per day, 200 mL per cup); Diets rich in xanthine, flavonoids, and other components (consultation);
• Within 48 hours before the first administration, consume grapefruit or beverages containing grapefruit; Consuming tea, coffee, chocolate, cola, or foods/beverages containing their main ingredients; Consuming a diet rich in xanthine, flavonoids, and other components; Or those who engage in vigorous exercise (consultation);
• Subjects with a history of drug abuse or positive results in urine drug abuse screening (consultation, examination);
• Any positive subject in screening period virus serum blood examination (hepatitis B surface antigen, hepatitis C antibody, HIV antigen antibody, Treponema pallidum antibody);
• During the screening period, if the physical examination, vital signs, electrocardiogram or laboratory test results are judged by clinical doctors to be abnormal and clinically significant, or if the QT interval is prolonged (female QT\>440 ms or male QT\>420 ms), or if fasting blood glucose exceeds the upper limit of normal values (examination);
• Pregnant or lactating women, or those who test positive for pregnancy (consultation, examination);

Sponsors & Collaborators

• Haisco Pharmaceutical Group Co., Ltd.: lead

Study Sites (1)

Zhongda Hospital, Southeast University

Nanjing, Jiangsu, China

Location

Related Publications (1)

• Chen X, Li Y, Ma G. Bioequivalence and Safety Study of Ranolazine Extended-Release Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: A Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Pharmacokinetic Study. Clin Ther. 2026 Jan;48(1):88-94. doi: 10.1016/j.clinthera.2025.11.002. Epub 2025 Nov 25.

  PMID: 41298182 DERIVED

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 27, 2025
• First Posted: July 8, 2025
• Study Start: September 6, 2020
• Primary Completion: November 9, 2020
• Study Completion: December 21, 2020
• Last Updated: July 8, 2025

Record last verified: 2025-06

Locations

CN (1)